FDA approval of imetelstat: a new era in the treatment of lower-risk myelodysplastic syndrome.

The recent FDA approval of Imetelstat marks a significant advancement in the treatment of lower-risk myelodysplastic syndrome (MDS), a clonal hematopoietic disorder primarily affecting the elderly and characterized by ineffective hematopoiesis and peripheral cytopenias. This narrative review explores the disease's underlying pathophysiology, diagnostic approach, and the evolving treatment landscape, with particular focus on Imetelstat, a novel telomerase inhibitor. Previously available treatments-including erythropoiesis-stimulating agents, lenalidomide, luspatercept, roxadustat, and azacitidine-have demonstrated variable efficacy and tolerability, with limited impact on long-term disease progression. Imetelstat, a 13-mer lipid-conjugated oligonucleotide, inhibits telomerase activity in malignant hematopoietic clones, thereby offering a mechanistically distinct, disease-modifying approach. Results from the IMerge Phase 3 trial demonstrated a statistically significant improvement in durable transfusion independence and hemoglobin response in patients refractory to erythropoiesis-stimulating agents, with an acceptable safety profile. The therapy not only addresses a critical unmet clinical need but also represents a shift toward precision and targeted molecular therapies in MDS management. Its approval underscores the importance of targeting fundamental disease mechanisms rather than merely alleviating symptoms. As additional data emerge from real-world settings and ongoing trials, Imetelstat may further reshape therapeutic algorithms and improve both quality of life and survival outcomes in this patient population.